Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

ognostic and pharmacogenomic evaluations in their updated treatment guidelines.

Targeted Agents in Combination are Entering Clinical Trials

The validated association of aggressive disease and the overexpression of HEr2 in any type or stage of breast cancer have created a $4 billion global market for trastuzumab (Herceptin; Genentech) in 2007. Still, nearly 50% of HEr2-positive patients do not respond to trastuzumab, and survival benefits are transient, often lasting under a year. Furthermore, side effects remain a significant problem. Despite these limitations, trastuzumab is the standard of treatment for both early stage and advanced or metastatic disease and is undergoing clinical trials in combination with numerous approved or novel anticancer agents.

Hundreds of clinical trials are underway combining approved targeted therapeutics with every applicable cytotoxic(s) with the goal of achieving incremental benefits. The greater opportunity, however, may lie in combining targeted therapeutics that address different points in one pathway or interacting pathways involved in angiogenesis, metastasis, drug resistance, and tumor growth and survival. This approach has entered the clinic; recently initiated trials are testing combinations of approved targeted therapeutics with each other. The full impact of combining target agents, however, will not be measured until approved and novel agents are combined in hundreds of different combinations for the treatment of hundreds of specific cancer indications.

Future Oncology Series Details ErbB Pathway-targeted Therapeutics

To date, ErbB pathway abnormalities, which occur in a large number of malignancies, have been the most extensively targeted. Currently, there are 7 approved agents targeting this pathway and over 620 clinical trials are ongoing with these agents in various combinations, mostly with cytotoxic agents but also with each other and with selected novel agents under clinical develo
'/>"/>

SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications ... months ended June 30, 2015. "Our ... growth, as revenues increased 47 percent year-over-year and ... Officer Michael Davin. "While our international results reflected ...
(Date:7/28/2015)... CRY ), a leading medical device and tissue ... today its results for the second quarter and first ... Chairman, President and Chief Executive Officer, said, "During the ... with solid progress on several of our top organizational ... a direct sales model in France, advancing our strategic ...
(Date:7/28/2015)... July 28, 2015 ANI Pharmaceuticals, Inc. (NASDAQ: ... to release its second quarter and year-to-date 2015 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
Breaking Medicine Technology:Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results 2
... Thousands of jobs in Texas supported by the ... – such as imposing new taxes in the Medicare ... From research to technical work, manufacturing to ... care services, the biopharmaceutical sector supports a broad array ...
... REDWOOD CITY, Calif. and SAO PAULO, Sept. 27, 2011 ... Raizen Energia S.A. today announced the signing of a ... ethanol process with enhanced performance economics. Raizen is Brazil,s ... the terms of the agreement, Raizen and Codexis will ...
Cached Medicine Technology:Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) ... from time to time and depending on market conditions, to repurchase shares of ... Repurchases will be made in open market or privately negotiated transactions in compliance ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... GA (PRWEB) , ... July 28, 2015 , ... ... been chosen as a “Top Doctor 2015” by Atlanta Magazine. In Atlanta Magazine's annual ... row by hundreds of her esteemed colleagues and peers in the metro area as ...
(Date:7/28/2015)... , ... July 28, 2015 , ... A new study ... Easy Fibromyalgia, Study Says " sheds light on a possible new treatment option for ... two months of regular HBOT sessions, at least five per week, patients experienced a ...
(Date:7/28/2015)... Irvine, CA (PRWEB) , ... July 28, 2015 ... ... risk of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of ... clinical cardiology is the identification of individuals with active yet undetected sub-clinical disease, ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
... a statement of Matthew L. Myers, President, Campaign ... ) The Campaign for Tobacco-Free Kids applauds ... role in Senate committee approval of legislation that ... regulatory authority over tobacco products, including the authority ...
... of Clinical Oncology. , ... Evanston, IL (Vocus) May 20, 2009 -- ... David J. Winchester , FACS, M.D., Chief of General Surgery and Surgical ... cancer has spread to the lymph nodes may not need a ...
... Alan B. Miller to Retain Chairman and CEO Positions Michael ... Pa., May 20 The Board of Directors of Universal ... nation,s largest hospital companies, today announced the election of Marc ... of Universal Health Service,s Chairman and Chief Executive, Alan Miller, ...
... On May 20, 2009, the US District Court for the ... AZN ) for an injunction barring Apotex (Apotex, ... AstraZeneca,s PULMICORT RESPULES (budesonide inhalation suspension) in the US. ... March 30, 2009, the US Food and Drug Administration granted ...
... SCHAUMBURG, Ill., May 20 Sagent Pharmaceuticals, Inc., ... it has raised $30 million in a second ... strategic investors. The round was again led by ... support upcoming product launches, development activities and strategic ...
Cached Medicine News:Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:Breast Cancer Patients May be Spared Additional Surgery 2Health News:Breast Cancer Patients May be Spared Additional Surgery 3Health News:Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services 2Health News:Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation 2
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
Medicine Products: